Yüklüyor......
New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib
Rearrangements in ALK gene and EML4 gene were first described in 2007. This genomic aberration is found in about 2%–8% of non-small-cell lung cancer (NSCLC) patients. Crizotinib was the first ALK tyrosine kinase inhibitor licensed for the treatment of metastatic ALK-positive NSCLC based on a randomi...
Kaydedildi:
| Yayımlandı: | Ther Clin Risk Manag |
|---|---|
| Yazar: | |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove Medical Press
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4863587/ https://ncbi.nlm.nih.gov/pubmed/27217763 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S87876 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|